The Financial Burden of Guideline-recommended Cancer Medications for Metastatic Urothelial Carcinoma

Costs associated with guideline-recommended treatments for metastatic urothelial carcinoma have significantly increased in recent years, mirroring trends for other cancers. The introduction of innovative agents has improved patient outcomes but places a substantial financial burden on health care systems. The pricing of cancer drugs is often not aligned with their clinical efficacy, emphasizing a need for value-based pricing. Our study underscores the importance of cost-effectiveness studies in shaping sustainable clinical strategies in an evolving treatment landscape.